GO:0005499 vitamin D binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005499 (vitamin D binding) is a molecular function describing the selective binding of vitamin D compounds, including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), by proteins such as vitamin D-binding protein (DBP/GC) and the vitamin D receptor (VDR).
• Vitamin D-binding protein (DBP, encoded by GC) is the major plasma carrier of vitamin D metabolites and also contributes to actin scavenging and immune modulation.
• The vitamin D receptor (VDR) binds 1,25-dihydroxyvitamin D3 with high affinity and mediates most genomic actions of vitamin D.
• Genetic polymorphisms in GC and VDR influence circulating vitamin D metabolite levels and have been associated with cancer risk, chronic liver disease, and other conditions.
• Studying vitamin D binding requires distinguishing total, free, and bioavailable vitamin D, because DBP concentration and affinity affect tissue delivery.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of GC, VDR, and related genes in vitamin D biology.
Description
Vitamin D binding (GO:0005499) is a molecular function that describes the selective interaction of proteins with vitamin D compounds, a group of fat-soluble secosteroids derived from delta-5,7 steroids that are central to calcium metabolism. The term encompasses binding to specific forms such as ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), as well as their hydroxylated metabolites. This function is essential for the transport, cellular uptake, and receptor-mediated signaling of vitamin D throughout the body. Researchers study vitamin D binding to understand how vitamin D is distributed, how it exerts its biological effects, and how dysregulation contributes to disease. The two most prominent protein families associated with this function are the vitamin D-binding protein (DBP, also known as GC) and the vitamin D receptor (VDR), which together coordinate vitamin D transport and genomic signaling. Because vitamin D influences calcium homeostasis, immune function, and cell proliferation, accurate measurement and functional characterization of vitamin D binding are critical for both basic and clinical research.
vitamin D binding At A Glance
| GO ID | GO:0005499 |
|---|---|
| GO term | vitamin D binding |
| Ontology | molecular_function |
| Synonym | calciferol binding; cholecalciferol binding; ergocalciferol binding |
| Major function | Binding to vitamin D and its metabolites, enabling transport, cellular uptake, and receptor-mediated signaling |
| Major proteins | Vitamin D-binding protein (DBP/GC), vitamin D receptor (VDR) |
| Related diseases | Chronic liver disease, malignant tumors, vitamin D deficiency, immune disorders |
| Research methods | CRISPR knockout/knock-in, radioligand binding assays, LC-MS/MS, immunoassays, transcriptomics |
What Is GO:0005499?
In the Gene Ontology, GO:0005499 (vitamin D binding) is defined as the binding to vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3). This molecular function is attributed to proteins that physically interact with vitamin D or its metabolites, such as the vitamin D-binding protein (DBP/GC) and the vitamin D receptor (VDR). The term is distinct from enzymatic activation of vitamin D, which involves cytochrome P450 enzymes, and from receptor-mediated signal transduction, although binding is a prerequisite for these downstream events.
Why Is vitamin D binding Important in Cell Biology?
Vitamin D binding is fundamental to human health because it governs the bioavailability and biological activity of vitamin D, a hormone-like secosteroid that regulates calcium and phosphate homeostasis, bone mineralization, immune responses, and cell growth. The vitamin D-binding protein (DBP) is the principal plasma carrier of vitamin D metabolites, and its concentration and genetic variants influence circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. The vitamin D receptor (VDR) mediates the genomic effects of 1,25-dihydroxyvitamin D3, and its binding to vitamin D is a prerequisite for transcriptional regulation of target genes. Dysregulation of vitamin D binding has been linked to chronic liver diseases, malignant tumors, and childhood health outcomes, making it a target for both diagnostic and therapeutic research.
• Vitamin D binding by DBP determines the transport and tissue delivery of vitamin D metabolites, affecting calcium homeostasis and bone health.
• The vitamin D receptor (VDR) binds 1,25-dihydroxyvitamin D3 to regulate gene expression, influencing cell differentiation, proliferation, and immune function.
• Genetic polymorphisms in GC (encoding DBP) are associated with variations in circulating vitamin D levels and risk of malignant tumors and other diseases.
• Altered vitamin D binding and DBP levels have been observed in chronic liver diseases, where they correlate with disease severity and prognosis.
• In childhood, DBP and vitamin D binding dynamics are important for growth, development, and immune maturation.
• Measurement of free versus total vitamin D requires understanding of DBP binding affinity and concentration, which is critical for clinical assessment.
• Vitamin D binding proteins also participate in actin scavenging and inflammatory responses, linking this function to broader physiological processes.
• CRISPR-based models of GC and VDR enable causal studies of vitamin D binding in health and disease.
• Vitamin D toxicity and pharmacokinetics are influenced by DBP binding, which affects the distribution and clearance of vitamin D metabolites.
• Research on vitamin D binding informs nutritional guidelines and therapeutic strategies for vitamin D deficiency.
Molecular Mechanism of vitamin D binding
Ligand recognition and binding specificity
In simple terms: Proteins that bind vitamin D recognize specific forms of the molecule, like vitamin D2 or D3, through shape and chemical interactions.
Vitamin D binding proteins exhibit selectivity for different vitamin D metabolites. The vitamin D-binding protein (DBP) binds 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with high affinity, while the vitamin D receptor (VDR) preferentially binds 1,25-dihydroxyvitamin D3. This specificity is determined by the ligand-binding pocket of the protein and the stereochemistry of the vitamin D molecule. The binding affinity of DBP for vitamin D metabolites is a key determinant of their circulating half-life and tissue availability.
Transport and distribution
In simple terms: DBP acts like a taxi, carrying vitamin D through the bloodstream to tissues where it is needed.
DBP is the major plasma carrier for vitamin D metabolites, transporting them from the liver and kidney to target tissues. The binding of vitamin D to DBP protects the hydrophobic secosteroid from rapid clearance and facilitates its delivery to cells expressing megalin and cubilin, which mediate uptake. The concentration of DBP and its saturation state influence the amount of free, bioavailable vitamin D.
Receptor-mediated signaling
In simple terms: When vitamin D enters a cell, it can bind to the vitamin D receptor, which then turns genes on or off.
The vitamin D receptor (VDR) is a nuclear receptor that binds 1,25-dihydroxyvitamin D3 with high affinity. Upon ligand binding, VDR undergoes conformational changes that allow it to heterodimerize with the retinoid X receptor (RXR) and bind to vitamin D response elements in DNA, thereby regulating transcription of target genes involved in calcium homeostasis, immune function, and cell cycle control. This genomic action is the primary mechanism by which vitamin D exerts its biological effects.
Regulation of binding proteins
In simple terms: The amounts of DBP and VDR in the body can go up or down depending on physiological state, affecting how much vitamin D is bound.
DBP levels are influenced by liver function, estrogen, and inflammatory states, and are reduced in chronic liver diseases. VDR expression is regulated by vitamin D itself, calcium, and other factors, creating feedback loops. Genetic polymorphisms in GC and VDR can alter binding affinity or protein levels, contributing to interindividual variability in vitamin D status.
Free versus bound vitamin D
In simple terms: Only the vitamin D that is not tightly bound to DBP is thought to be easily available to cells.
The free hormone hypothesis posits that the unbound fraction of vitamin D is biologically active, while DBP-bound vitamin D serves as a reservoir. Therefore, measuring total vitamin D alone may not reflect its functional status; calculating free and bioavailable vitamin D requires knowledge of DBP concentration and binding affinity. This has implications for diagnosing vitamin D deficiency and for interpreting epidemiological studies.
Key Genes Involved in GO:0005499 vitamin D binding
The following genes encode proteins that directly or indirectly participate in vitamin D binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GC | Encodes vitamin D-binding protein (DBP), the main plasma carrier of vitamin D metabolites | Polymorphisms linked to vitamin D levels and disease risk; target for KO and knock-in studies |
| VDR | Encodes the vitamin D receptor, a nuclear receptor that binds 1,25-dihydroxyvitamin D3 | Mediates genomic actions of vitamin D; mutations cause hereditary vitamin D-resistant rickets |
| CYP2R1 | Cytochrome P450 enzyme that 25-hydroxylates vitamin D | Affects production of 25-hydroxyvitamin D, the main circulating metabolite |
| CYP27B1 | 1-alpha-hydroxylase that converts 25-hydroxyvitamin D to its active form | Critical for generating 1,25-dihydroxyvitamin D3, the VDR ligand |
| CYP24A1 | 24-hydroxylase that inactivates vitamin D metabolites | Regulates vitamin D catabolism and prevents toxicity |
| LRP2 | Encodes megalin, a receptor that mediates cellular uptake of DBP-vitamin D complexes | Important for renal and tissue delivery of vitamin D |
| CUBN | Encodes cubilin, a co-receptor for megalin in vitamin D uptake | Facilitates endocytosis of DBP-bound vitamin D |
| RXRA | Retinoid X receptor alpha, heterodimerization partner of VDR | Essential for VDR-mediated transcription |
| NCOA1 | Nuclear receptor coactivator 1, enhances VDR transcriptional activity | Modulates vitamin D signaling |
| NCOR1 | Nuclear receptor corepressor 1, represses VDR target genes | Regulates vitamin D-responsive gene expression |
| STAT1 | Signal transducer and activator of transcription 1, interacts with VDR | Links vitamin D signaling to immune responses |
| RUNX2 | Transcription factor involved in osteoblast differentiation, regulated by VDR | Mediates vitamin D effects on bone |
| SPP1 | Osteopontin, a VDR target gene | Biomarker of vitamin D action in bone and immune cells |
| TRPV6 | Calcium channel regulated by VDR | Mediates vitamin D-dependent calcium absorption |
| S100G | Calbindin-D9k, a VDR target involved in calcium transport | Marker of vitamin D activity in intestine |
| CDKN1A | p21, a cell cycle inhibitor induced by VDR | Links vitamin D binding to growth arrest and differentiation |
| CAMP | Cathelicidin antimicrobial peptide, induced by VDR in immune cells | Connects vitamin D binding to innate immunity |
| FN1 | Fibronectin, interacts with DBP and actin | May influence DBP-mediated processes in tissue remodeling |
How Is vitamin D binding Regulated?
Vitamin D binding is regulated at multiple levels. DBP (GC) expression is influenced by liver function, estrogen, and inflammatory cytokines, and its plasma concentration decreases in chronic liver disease. VDR expression and activity are modulated by 1,25-dihydroxyvitamin D3 itself through feedback mechanisms, as well as by calcium, parathyroid hormone, and immune signals. Genetic polymorphisms in GC and VDR affect binding affinity and protein levels, contributing to interindividual variability in vitamin D status and disease susceptibility. Additionally, the availability of vitamin D metabolites for binding is controlled by cytochrome P450 enzymes (CYP2R1, CYP27B1, CYP24A1) that catalyze hydroxylation and inactivation.
vitamin D binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GC | Chronic liver disease; altered vitamin D transport | GC knockout hepatocyte cell lines; liver-specific KO mice |
| GC | Cancer risk (breast, prostate, colorectal) | GC polymorphism knock-in cell models; cancer cell lines with DBP overexpression |
| VDR | Hereditary vitamin D-resistant rickets; cancer; immune disorders | VDR knockout cell lines; point mutations in ligand-binding domain |
| CYP27B1 | Vitamin D-dependent rickets type I | CYP27B1 knockout cells; rescue with 1,25-dihydroxyvitamin D3 |
| LRP2 | Renal vitamin D wasting; impaired uptake | LRP2 knockout kidney cell models; megalin-deficient mice |
Vitamin D binding in chronic liver diseases
Chronic liver diseases are associated with reduced synthesis of DBP and altered vitamin D metabolism, leading to lower circulating levels of 25-hydroxyvitamin D and its binding protein. This contributes to vitamin D deficiency, hepatic osteodystrophy, and immune dysfunction in patients with cirrhosis and other liver conditions. Research has focused on the role of DBP as a biomarker of liver function and on the therapeutic potential of vitamin D supplementation in these populations.
Vitamin D binding and cancer
Polymorphisms in the GC gene encoding DBP have been associated with altered risk of several malignancies, including breast, prostate, and colorectal cancers, possibly through effects on vitamin D bioavailability and immune modulation. The vitamin D receptor (VDR) mediates antiproliferative and prodifferentiation effects of 1,25-dihydroxyvitamin D3 in cancer cells, and its binding to vitamin D is essential for these actions. Epidemiological studies suggest that adequate vitamin D binding and signaling may be protective against cancer development and progression.
Vitamin D binding in childhood health and development
DBP and vitamin D binding dynamics are important during childhood for growth, bone development, and immune maturation. Variations in GC and VDR genes have been linked to differences in vitamin D status and susceptibility to infections and autoimmune conditions in children. Understanding vitamin D binding in pediatric populations may inform nutritional recommendations and early interventions.
Vitamin D binding in other pathophysiological conditions
Altered vitamin D binding has been implicated in a range of conditions, including chronic kidney disease, autoimmune disorders, and infectious diseases. DBP also functions as an actin scavenger, and its depletion in acute illness may affect both vitamin D transport and tissue repair. The free versus bound vitamin D ratio is altered in pregnancy, obesity, and inflammation, complicating the assessment of vitamin D status.
From vitamin D binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GC affect vitamin D transport and tissue distribution? | GC knockout cell lines (e.g., HepG2) and liver-specific KO mice |
| How do GC polymorphisms alter binding affinity for vitamin D metabolites? | Point-mutation knock-in of GC variants in HEK293 or HepG2 cells |
| What is the effect of VDR ligand-binding domain mutations on vitamin D signaling? | VDR point-mutation knock-in cell lines; reporter assays |
| Can overexpression of DBP rescue vitamin D deficiency in vitro? | DBP overexpression in hepatic or renal cell lines |
| How does tagged DBP behave in live cells? | Tagged knock-in of GC with fluorescent or affinity tags |
| What genes are regulated by vitamin D binding and VDR activation? | CRISPR library screening with VDR knockout and transcriptomics |
How to Study the vitamin D binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Concentration of vitamin D metabolites | Clinical assessment of vitamin D status |
| Immunoassay | DBP or 25-hydroxyvitamin D levels | Large-scale epidemiological studies |
| Radioligand binding | Affinity and capacity of DBP or VDR for vitamin D | Characterizing mutant proteins |
| RNA-seq | Transcriptional changes upon vitamin D binding | Identifying VDR target genes |
| Proteomics | Protein expression and interactions | Quantifying DBP in plasma or cells |
| Fluorescence microscopy | Subcellular localization of DBP or VDR | Studying trafficking and uptake |
| CRISPR screening | Genes required for vitamin D binding or signaling | Functional genomics of vitamin D pathways |
Quantifying vitamin D metabolites and DBP
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for measuring vitamin D metabolites, including 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, with high sensitivity and specificity. Immunoassays are widely used for DBP quantification, but they may vary in accuracy. Free and bioavailable vitamin D can be calculated from total vitamin D, DBP, and albumin concentrations using affinity constants.
Binding assays
Radioligand binding assays using tritiated 1,25-dihydroxyvitamin D3 are used to measure the affinity and capacity of VDR and DBP for vitamin D metabolites. Surface plasmon resonance and isothermal titration calorimetry provide kinetic and thermodynamic parameters of binding. These methods help characterize the effects of genetic variants on vitamin D binding.
Transcriptomic and proteomic profiling
RNA sequencing (RNA-seq) of cells treated with vitamin D or with VDR/DBP knockout can identify genes regulated by vitamin D binding and signaling. Proteomic approaches can quantify DBP and other vitamin D-related proteins in plasma or cell lysates. These methods reveal downstream pathways affected by altered vitamin D binding.
Imaging and cellular localization
Fluorescence microscopy of tagged DBP or VDR can visualize their subcellular localization and trafficking in response to vitamin D. Live-cell imaging using fluorescent vitamin D analogs can track uptake and binding dynamics. These techniques complement biochemical assays by providing spatial and temporal information.
How CRISPR Can Be Used to Study GO:0005499 vitamin D binding
Knockout
CRISPR-Cas9 knockout of GC or VDR in cell lines such as HepG2 or HEK293 can abolish vitamin D binding and transport, enabling studies of downstream effects on gene expression, calcium handling, and immune function. Knockout models help distinguish the roles of DBP versus VDR in vitamin D biology.
Point Mutation
Introducing specific point mutations in GC or VDR via CRISPR base editing or homology-directed repair allows researchers to test the functional impact of naturally occurring polymorphisms on vitamin D binding affinity and signaling. For example, mutations in the VDR ligand-binding domain can mimic hereditary vitamin D-resistant rickets.
Knock-in
Knock-in of tagged GC or VDR (e.g., GFP or HA tags) enables real-time tracking of protein localization and interactions in live cells. Knock-in of disease-associated variants can create isogenic models to study their effects on vitamin D binding and metabolism.
Overexpression
Overexpression of DBP or VDR in cell lines can enhance vitamin D binding capacity and amplify downstream signaling, useful for biochemical assays and drug screening. Overexpression models also help assess whether increased binding protects against vitamin D deficiency or toxicity.
How EDITGENE Supports vitamin D binding Research
Researchers studying vitamin D binding-related genes often need to determine whether a candidate gene is causally involved in vitamin D transport, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to create precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for vitamin D binding research.
Frequently Asked Questions About vitamin D binding
What is GO:0005499 vitamin D binding?
GO:0005499 is a Gene Ontology molecular function term defined as binding to vitamin D, a group of fat-soluble secosteroids derived from delta-5,7 steroids that are central to calcium metabolism. It includes binding to ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3).
What genes are involved in vitamin D binding?
The major genes are GC, which encodes vitamin D-binding protein (DBP), and VDR, which encodes the vitamin D receptor. Other related genes include CYP2R1, CYP27B1, CYP24A1, LRP2, and CUBN.
How does vitamin D-binding protein work?
DBP binds vitamin D metabolites in the bloodstream, transports them to target tissues, and protects them from rapid clearance. It also facilitates cellular uptake via megalin and cubilin receptors.
What is the difference between DBP and VDR?
DBP is a plasma carrier protein that transports vitamin D, while VDR is a nuclear receptor that binds 1,25-dihydroxyvitamin D3 inside cells to regulate gene expression.
What diseases are associated with vitamin D binding?
Altered vitamin D binding has been linked to chronic liver diseases, cancer, childhood health conditions, chronic kidney disease, and immune disorders.
How is vitamin D binding measured?
Vitamin D metabolites are measured by LC-MS/MS or immunoassays, while DBP levels are quantified by immunoassays. Binding affinity can be assessed by radioligand binding assays.
What are the synonyms for GO:0005499?
The synonyms are calciferol binding, cholecalciferol binding, and ergocalciferol binding.
Why is free vitamin D important?
According to the free hormone hypothesis, only unbound vitamin D is biologically active. DBP-bound vitamin D serves as a reservoir, so measuring total vitamin D alone may not reflect functional status.
Can CRISPR be used to study vitamin D binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models of GC and VDR enable causal studies of vitamin D binding in health and disease.
What is the role of vitamin D-binding protein in liver disease?
In chronic liver diseases, DBP synthesis is reduced, leading to lower circulating vitamin D levels and contributing to deficiency and related complications.
Conclusion
Vitamin D binding (GO:0005499) is a critical molecular function that governs the transport, cellular uptake, and receptor-mediated signaling of vitamin D. The vitamin D-binding protein (DBP/GC) and the vitamin D receptor (VDR) are the key players, and their genetic variants influence vitamin D status and disease susceptibility. Understanding this function has broad implications for cancer, chronic liver disease, childhood development, and immune function. CRISPR-based models offer powerful tools to dissect the causal roles of GC, VDR, and related genes, and EDITGENE provides end-to-end services to support such research.
References
- 1. Delrue C et al.. 2023. Vitamin D and Vitamin D-Binding Protein in Health and Disease.. Int J Mol Sci 24(5) PMID: 36902073
- 2. Pop TL et al.. 2022. The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases.. Int J Mol Sci 23(18) PMID: 36142636
- 3. Alonso N et al.. 2023. Vitamin D Metabolites: Analytical Challenges and Clinical Relevance.. Calcif Tissue Int 112(2):158-177 PMID: 35238975
- 4. Delrue C et al.. 2024. Investigating Vitamin D-Binding Protein's Role in Childhood Health and Development.. Int J Mol Sci 25(11) PMID: 38892458
- 5. Fraser DR et al.. 2025. Commentary: Cellular functions of vitamin D-binding protein.. Comp Biochem Physiol A Mol Integr Physiol 305:111848 PMID: 40147814
- 6. Jones G. 2008. Pharmacokinetics of vitamin D toxicity.. Am J Clin Nutr 88(2):582S-586S PMID: 18689406
- 7. Rozmus D et al.. 2020. Vitamin D Binding Protein (VDBP) and Its Gene Polymorphisms-The Risk of Malignant Tumors and Other Diseases.. Int J Mol Sci 21(21) PMID: 33105665
- 8. Xie Z et al.. 2020. Editorial: Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions.. Front Endocrinol (Lausanne) 11:40 PMID: 32117066
